Clinical effects of comprehensive treatments for FIGO Stage IIB adenocarcinoma/adenosquamous carcinoma of the cervix

To evaluate the clinical effects of comprehensive treatments for the FIGO Stage IIB adenocarcinoma (AC) / adenosquamous carcinoma (ASC) of cervix of patients from four institutions between 2000 and 2009 with Stage IIB AC/ASC of cervix that were included and divided into two groups. Both groups received initial cisplatin-based neoadjuvant chemotherapy (NACT) treatment. Radical surgery (RS, n=70) group subsequently underwent surgery followed by adjuvant chemo-radiotherapy, while the radiotherapy (RT, n=70) group received the standard concurrent chemo-radiotherapy alone. Differences in outcomes were compared. Multivariate analysis was used. The overall survival (OS) was 74.3% vs. 52.9% (p = 0.002) and progression free survival (PFS) rates were 64.3% vs. 44.3 %( p = 0.007) in each group. Complications in the RS group were acceptable. Presence of lymph node metastasis was a significant factor in determining OS. The authors conclude that NACT combined with RS followed by adjuvant chemo-radiotherapy is a promising treatment option for Stage IIB AC/ASC of the cervix.

Cervical cancer; Concurrent chemo-radiation; FIGO stage IIB; Adenocarcinoma/adenosquamous carcinoma; Radical surgery;

Prognostic factors.

[1] Smith H.O., Tiffany M.F., Qualls C.R., Key C.R.: “The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study”. Gynecol. Oncol., 2000, 78, 97.

[2] Chen J.L., Huang C.Y., Huang Y.S., Chen R.J., Wang C.W., Chen Y.H., et al.: “Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy”. Acta Obstet. Gynecol. Scand., 2014, 93, 661.

[3] Koh W.J., Greer B.E., Abu-Rustum N.R., Apte S.M., Campos S.M., Chan J., et al.: “Cervical cancer”. J. Natl. Compr. Canc. Netw., 2013, 11, 320.

[4] Chai Y., Wang T., Wang J., Yang Y., Gao Y., Gao J., et al.: “Radical hysterectomy with adjuvant radiotherapy versus radical radiotherapy for FIGO stage IIB cervical cancer”. BMC Cancer, 2014, 14, 63.

[5] Kasamatsu T., Onda T., Sawada M., Kato T., Ikeda S.: “Radical hysterectomy for FIGO stage IIB cervical cancer: clinicopathological characteristics and prognostic evaluation”. Gynecol. Oncol., 2009, 114, 69.

[6] Shimada M., Nishimura R., Nogawa T., Hatae M., Takehara K., Yamada H., et al.: “Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjuvant radiotherapy following radical surgery: SGSG/TGCU Intergroup Surveillance”. Mol. Clin. Oncol., 2013, 1, 780

[7] Look K.Y., Brunetto V.L., Clarke-Pearson D.L., Averette H.E., Major F.J., Alvarez R.D., et al.: “An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study”. Gynecol. Oncol., 1996, 63, 304.

[8] Irie T., Kigawa J., Minagawa Y., Itamochi H., Sato S., Akeshima R., et al.: “Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy”. Eur. J. Surg. Oncol., 2000, 26, 464.

[9] Rose P.G., Java J.J., Whitney C.W., Stehman F.B., Lanciano R., Thomas G.M.: “Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation”. Gynecol. Oncol., 2014, 135, 208.

[10] Mabuchi S., Morishige K., Isohashi F., Yoshioka Y., Takeda T., Yamamoto T., et al.: “Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors”. Gynecol. Oncol., 2009, 115, 482.

[11] Mabuchi S., Morishige K., Fujita M., Tsutsui T., Sakata M., Enomoto T., et al.: “The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy”. Gynecol. Oncol., 2009, 113, 200.

[12] Minig L., Colombo N., Zanagnolo V., Landoni F., Bocciolone L., Cardenas-Rebollo J.M., et al.: “Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB”. Int. J. Gynecol. Cancer, 2013, 23, 1647.

[13] Bogani G., Cromi A., Serati M., Di Naro E., Casarin J., Marconi N., et al.: “A prospective case-control study on the impact of neoadjuvant chemotherapy on surgery-related outcomes of laparoscopic radical hysterectomy”. Anticancer Res., 2014, 34, 5703.

[14] Mabuchi S., Okazawa M., Isohashi F., Matsuo K., Ohta Y., Suzuki O., et al.: “Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage IIB cervical cancer”. Gynecol. Oncol., 2011, 123, 241.

[15] Katsumata N., Yoshikawa H., Kobayashi H., Saito T., Kuzuya K., Nakanishi T., et al.: “Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102)”. Br. J. Cancer, 2013, 108, 1957.

[16] Choi Y.S., Sin J.I., Kim J.H., Ye G.W., Shin I.H., Lee T.S.: “Survival benefits of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy in locally advanced chemoresistant cervical cancer”. J. Korean Med. Sci., 2006, 21, 683.

[17] Tang J., Tang Y., Yang J., Huang S.: “Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma”. Gynecol. Oncol., 2012, 125, 297.

[18] Morris M., Eifel P.J., Lu J., Grigsby P.W., Levenback C., Stevens R.E., et al.: “Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer”. N. Engl. J. Med., 1999, 340, 1137.

[19] Lee Y.Y., Choi C.H., Kim T.J., Lee J.W., Kim B.G., Lee J.H., et al.: “A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA”. Gynecol. Oncol., 2011, 120, 439.

[20] Farley J.H., Hickey K.W., Carlson J.W., Rose G.S., Kost E.R., Harrison T.A.: “Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma”. Cancer, 2003, 97, 2196.

[21] Tsubamoto H., Yamamoto S., Kanazawa R., Sakane R., Honda O., Kobayashi K., et al.: “Prognostic factors for locally advanced cervical cancer treated with neoadjuvant intravenous and transuterine arterial chemotherapy followed by radical hysterectomy”. Int. J. Gynecol. Cancer, 2013, 23, 1470.

[22] Intaraphet S., Kasatpibal N., Sogaard M., Khunamornpong S., Patumanond J., Chandacham A., et al.: “Histological type-specific prognostic factors of cervical small cell neuroendocrine carcinoma, adenocarcinoma, and squamous cell carcinoma”. Onco. Targets Ther., 2014, 7, 1205.

[23] Niibe Y., Kenjo M., Onishi H., Ogawa Y., Kazumoto T., Ogino I., et al.: “High-dose-rate intracavitary brachytherapy combined with external beam radiotherapy for stage IIIb adenocarcinoma of the uterine cervix in Japan: a multi-institutional study of Japanese Society of Therapeutic Radiology and Oncology 2006-2007 (study of JASTRO 2006-2007)”. Jpn. J. Clin. Oncol., 2010, 40, 795.

[24] Huang Y.T., Wang C.C., Tsai C.S., Lai C.H., Chang T.C., Chou H.H., et al.: “Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy”. Int. J. Radiat. Oncol. Biol. Phys., 2012, 84, 420.

[25] Vargo J.A., Boisen M.M., Comerci J.T., Kim H., Houser C.J., Sukumvanich P., et al.: “Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria”. Gynecol. Oncol., 2014, 135, 190.